Ready to challenge GlaxoSmithKline and Merck, India's Bharat Biotech has won WHO prequalification for its rotavirus vaccine Rotavac.
The WHO stopped classifying Zika as an emergency in late 2016, but Takeda has pressed ahead with its program, winning an FDA fast-track designation.
Here is some other vaccine news of note for the week.
As investigations in the Philippines proceed, Sanofi Pasteur has agreed to refund the cost of unused Dengvaxia doses worth about $28 million.
Following mass immunization program halt, Dengvaxia’s marketing authorization in the Philippines has been put on hold for a year.
More than 70 mothers in the Philippines whose children were vaccinated against dengue filed a criminal complaint against government and company officials.
As Philippines lawmakers continue probing the country's now-controversial dengue immunization program, a former president has spoken up to defend it.
Philippines' health secretary plans to ask Sanofi for a Dengvaxia refund and to sue the drugmaker amid worries about the dengue shot's safety.
On the heels of a safety warning, the Philippines' FDA ordered Sanofi to pull its Dengvaxia shot from the market.
The Philippines halted its dengue vaccination program after Sanofi flagged serious risks for recipients who'd never been infected with the virus.